Minimal Residual Disease Clinical Trial
Official title:
A Study of Chidamide With AZA in MRD Positive AML After Transplant
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.
Investigators proposed Chidamide combined with azacitidine as the prospective treatment for MRD-positive AML patients before and after transplantation, hoping to reduce the recurrence rate of transplantation and improve the transplantation effect. The efficacy and safety of the method will be verified by this clinical study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04044560 -
Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02458014 -
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
|
Phase 2 | |
Active, not recruiting |
NCT03233854 -
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04853017 -
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06358430 -
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
|
Phase 1 | |
Not yet recruiting |
NCT05603156 -
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
|
N/A | |
Withdrawn |
NCT03699384 -
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05601830 -
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
|
Phase 1 | |
Terminated |
NCT03272633 -
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
|
Early Phase 1 | |
Recruiting |
NCT03241940 -
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
Completed |
NCT03096782 -
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
|
Phase 2 | |
Completed |
NCT05093192 -
Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia
|
N/A | |
Recruiting |
NCT06230185 -
ctDNA Based MRD Testing for NAC Monitoring in TNBC
|
||
Recruiting |
NCT02400827 -
Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors
|
N/A | |
Recruiting |
NCT02400970 -
Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors
|
N/A | |
Active, not recruiting |
NCT01894477 -
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT04920188 -
Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
|
||
Completed |
NCT02714790 -
Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia
|
N/A |